Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and ...
Niagen Bioscience, Inc. (formerly ChromaDex) is a Los Angeles-based biotechnology company focused on promoting healthy aging. Founded in 1999 by Frank Jaksch Jr., the company has evolved into the global leader in NAD+ research and innovation. Its core platform is Niagen (nicotinamide riboside chloride), a proprietary ingredient that boosts NAD+ ...Niagen Bioscience, Inc. (formerly ChromaDex) is a Los Angeles-based biotechnology company focused on promoting healthy aging. Founded in 1999 by Frank Jaksch Jr., the company has evolved into the global leader in NAD+ research and innovation. Its core platform is Niagen (nicotinamide riboside chloride), a proprietary ingredient that boosts NAD+ levels, which are critical for cellular energy and metabolism. The company markets Tru Niagen, a dietary supplement containing Niagen, directly to consumers and also supplies Niagen to other brands. Financially, Niagen Bioscience reported an annual revenue of approximately $129 million (TTM), with a gross profit margin of 64.2% and a net profit margin of 12.4%, despite historical losses. The company maintains a strong balance sheet with a current ratio of 6.5 and minimal debt. Key executives include CEO Robert Fried, who has been instrumental in commercializing Tru Niagen, and co-founder Frank Jaksch Jr., who leads research and strategy. The company emphasizes rigorous scientific validation, with multiple clinical trials supporting the efficacy of Niagen. Its ISO-accredited labs ensure quality. With a market cap of around $248 million, Niagen Bioscience aims to expand its reach in the healthy aging market, leveraging partnerships and ongoing innovation. The company changed its name from ChromaDex to Niagen Bioscience in March 2025 to reflect its focus, and its ticker changed to NAGE. Despite competition in the NAD+ space, Niagen Bioscience remains a pioneer and trusted authority in the field.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$129.4M
+29.9%
-5.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$17.4M
+103.3%
-84.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+64.3%
+3.9%
+2.2%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+11.0%
+42.4%
-53.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+13.4%
+56.4%
-83.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$13.1M
+10.0%
+313.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+10.2%
-15.3%
+325.9%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
3.7%
-36.0%
-9.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.86x
+36.1%
+41.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Ladies and gentlemen, thank you for standing by, and welcome to Niagen Bioscience Inc.'s First Quarter 2026 Earnings Conference Call. My name is Karina, and I will be the conference operator today. [Operator Instructions] As a reminder, this conference call is being recorded. Earlier today, Niagen Bioscience issued a press release announcing its financial results for the first quarter of 2026. If you have not reviewed this information, it is available within the Investor Relations section of Niagen Bioscience's website at www.niagenbioscience.com. I would now like to turn the call over to Lauren Borzansky, Assistant Controller. Please go ahead.
Lauren Rittman-Borzansky: Good afternoon, and welcome to Niagen Bioscience Inc.'s First Quarter 2026 Conference Call. Joining me today are our Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao. Dr. Shao will be joining the call for Q&A. Before we begin, I'd like to remind everyone that today's call may include forward-looking statements. These statements relate to, among other things, our research and development activities, clinical trial plans and timing, regulatory filings, expansion into new markets, business development opportunities and our expected financial and operating performance. These statements are based on our current expectations as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to our most recent Form 10-Q and other filings with the SEC. We undertake no obligation to update these statements, except as required by law. In addition, we may reference certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures can be found in today's earnings release and presentation, both available in the Investor Relations section of our website. With that, it's now my pleasure to turn the call over to our CEO, Rob Fried.
Robert Fried: Thank you, Lauren. Good afternoon, everyone, and thank you for joining us on today's investor call. In the first quarter, we delivered $31.5 million in revenue, a 5% year-over-year growth, excluding revenue from the recently divested reference standard business. We generated net income of $6.3 million and ended the quarter with $66.5 million in cash and no debt. We had an increase in working capital of about $5.4 million from the prior quarter, leaving a total of $82.3 million. The core e-commerce business grew 14% year-over-year. The direct-to-consumer website grew twice as fast as Amazon. As anticipated, two of our customers did not order this quarter as much as they did a year ago, which impacted overall growth, but we do see promising indicators to start the year. The awareness around Niagen and the benefits of NAD supplementation continues to gain media attention. Over the last year, we've garnered many features with …
